MX2020002702A - Metodo de tratamiento. - Google Patents
Metodo de tratamiento.Info
- Publication number
- MX2020002702A MX2020002702A MX2020002702A MX2020002702A MX2020002702A MX 2020002702 A MX2020002702 A MX 2020002702A MX 2020002702 A MX2020002702 A MX 2020002702A MX 2020002702 A MX2020002702 A MX 2020002702A MX 2020002702 A MX2020002702 A MX 2020002702A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- lymphoma
- treatment method
- treating
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un método para tratar el linfoma en un sujeto y, más particularmente, para tratar el linfoma de Hodgkin (HL) y el linfoma no Hodgkin (NHL). El método comprende administrar al sujeto una cantidad efectiva de una proteína de unión a CD83. La invención se refiere, además, a métodos para diagnosticar y evaluar el linfoma en un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017903726A AU2017903726A0 (en) | 2017-09-13 | Treatment method | |
PCT/AU2018/050987 WO2019051541A1 (en) | 2017-09-13 | 2018-09-12 | METHOD OF TREATMENT |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002702A true MX2020002702A (es) | 2020-10-05 |
Family
ID=65722240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002702A MX2020002702A (es) | 2017-09-13 | 2018-09-12 | Metodo de tratamiento. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200277396A1 (es) |
EP (1) | EP3681536A4 (es) |
JP (1) | JP2020533384A (es) |
KR (1) | KR20200066613A (es) |
CN (1) | CN111565749A (es) |
AU (2) | AU2018333275A1 (es) |
CA (1) | CA3074379A1 (es) |
MX (1) | MX2020002702A (es) |
SG (1) | SG11202001806TA (es) |
WO (1) | WO2019051541A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2899960C (en) | 2013-02-01 | 2022-05-03 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
US20200108098A1 (en) * | 2018-02-23 | 2020-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
WO2021258140A1 (en) * | 2020-06-23 | 2021-12-30 | Kira Biotech Pty Limited | Cd83 binding protein conjugates for treating lymphoma |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2899960C (en) * | 2013-02-01 | 2022-05-03 | Transbio Ltd | Anti-cd83 antibodies and use thereof |
CN105899535A (zh) * | 2013-12-17 | 2016-08-24 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法 |
NZ731491A (en) * | 2014-10-23 | 2021-12-24 | Kira Biotech Pty Ltd | Cd83 binding proteins and uses thereof |
MX2017005751A (es) * | 2014-11-03 | 2018-04-10 | Genentech Inc | Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40. |
-
2018
- 2018-09-12 EP EP18855410.9A patent/EP3681536A4/en not_active Withdrawn
- 2018-09-12 AU AU2018333275A patent/AU2018333275A1/en not_active Abandoned
- 2018-09-12 JP JP2020515156A patent/JP2020533384A/ja active Pending
- 2018-09-12 KR KR1020207007951A patent/KR20200066613A/ko not_active Application Discontinuation
- 2018-09-12 WO PCT/AU2018/050987 patent/WO2019051541A1/en unknown
- 2018-09-12 US US16/646,745 patent/US20200277396A1/en not_active Abandoned
- 2018-09-12 CN CN201880067825.1A patent/CN111565749A/zh active Pending
- 2018-09-12 CA CA3074379A patent/CA3074379A1/en not_active Abandoned
- 2018-09-12 SG SG11202001806TA patent/SG11202001806TA/en unknown
- 2018-09-12 MX MX2020002702A patent/MX2020002702A/es unknown
-
2022
- 2022-06-10 AU AU2022204077A patent/AU2022204077A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20200066613A (ko) | 2020-06-10 |
AU2018333275A1 (en) | 2020-04-09 |
AU2022204077A1 (en) | 2022-06-30 |
SG11202001806TA (en) | 2020-03-30 |
JP2020533384A (ja) | 2020-11-19 |
EP3681536A1 (en) | 2020-07-22 |
EP3681536A4 (en) | 2021-06-09 |
CA3074379A1 (en) | 2019-03-21 |
US20200277396A1 (en) | 2020-09-03 |
WO2019051541A1 (en) | 2019-03-21 |
CN111565749A (zh) | 2020-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017225061B2 (en) | Biomarkers and methods of treating PD-1 and PD-L1 related conditions | |
PH12017502354A1 (en) | Humanized and affinity matured antibodies to fcrh5 and methods of use | |
MX2016009010A (es) | Anticuerpos anti-gen de activacion de linfocitos (lag-3) para tratar neoplasias hematologicas. | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
MY196858A (en) | Method | |
ZA202101797B (en) | Hair treatment compositions, methods, and kits for treating hair | |
GB2515712A (en) | System for binding bone | |
MX2020002702A (es) | Metodo de tratamiento. | |
EA036102B9 (ru) | Терапевтические средства с углевод-опосредованной адресной доставкой | |
PH12017502120B1 (en) | A method and an apparatus for forming a lignin fraction, a lignin composition and its use | |
MX2018008882A (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
MX356933B (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
AU2018337076A1 (en) | Method of treatment | |
MX2020002216A (es) | Metodos y composiciones para detectar y tratar endometriosis. | |
NZ722600A (en) | Methods of treating mild brain injury | |
EP3571310A4 (en) | COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT OF PEROXISOMAL DISEASES | |
MX2021009079A (es) | Metodos para tratar el mieloma multiple. | |
TN2018000197A1 (en) | Compositions and methods for assessing the risk of cancer occurrence | |
MX2016006584A (es) | Métodos y composiciones para tratar los depósitos de amiloide. | |
MX2020003395A (es) | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. | |
MX2016002308A (es) | Tratamiento del mieloma multiple. | |
EP3823593A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTISM | |
MX2016002307A (es) | Tratamiento para el cancer. | |
WO2020097079A8 (en) | Methods for treating traumatic brain injury | |
MX2016001223A (es) | Metodo para el pronostico de la eficacia de la inmunoterapia oral para el tratamiento de la alergia a las proteinas de leche de vaca. |